Survival and prognostic factors of lymphadenectomy in endometrial cancer: a Tunisian single center experience

Ines Ben Safta, Olfa Jaidane, Houyem Mansouri, Raoudha Doghri, Selma Gadria, Karima Mrad, Jamel Ben Hassouna, Khaled Rahal


Background: Endometrial cancer (EC) is the most common pelvic gynecological cancer. The purpose of the present study is to identify histoprognostic risk factors for lymph node involvement, evaluate the impact of lymphadenectomy on relapse and overall survival and assess prognostic factors influencing the survival rates in endometrial cancer.

Methods: This was a retrospective study of 249 cases of endometrial cancer, over a period of 16 years (2000-2015). We analyzed the clinical, pathological features and outcome of our patients. Curves of overall and recurrence-free survival were performed.

Results: In our cohort, stage IA was found in 46.6% of cases, stage IB in 14.5%, stage II in 13.7%, stage IIIA in 3.6%, stage IIIB in 2%, stage IIIC1 in 8.8%, stage IIIC2 in 4.4% and stage IV in 6.4%. The histologic type (p=0.02, OR=2.702, CI [1.169; 6.25]), myometrial invasion (p<0.001, OR=4.524, CI [1.960; 10.416]), lymphovascular space invasion (p=0.047, OR=2.267; CI [1.013; 5.076]) were the only independent factors of lymph node invasion in multivariate analysis. 5-years overall and recurrence free survival was 76.3% and 81.5%, respectively. Overall survival at 5 years was 64.6% with a lymph node ratio of less than 10%, 22.2% with a lymph node ratio between 10 and 50%, and zero with a lymph node ration greater than 50% (p=0.016). By studying the number of lymph nodes removed during lymphadenectomy, survival trend to be improved when the lymph node count increased.

Conclusions: The lymphadenectomy has an incontestable diagnostic and prognostic value. Present retrospective study showed the therapeutic interest of lymph node dissection in endometrial cancers.


Endometrial neoplasm, Lymph node excision, Prognosis, Survival

Full Text:



Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7-30.

Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet. 2009;105(2):103-4.

Medel NIB, Herzog TJ, Deutsch I, Burke WM, Sun X, Lewin SN, et al. Comparison of the prognostic significance of uterine factors and nodal status for endometrial cancer. Am J Obstet Gynecol. 2011;204(3):248.e1-248.e7.

Frost JA, Webster KE, Bryant A, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Libr. 2017.

Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. The Lancet. 2016;387(10023):1094-108.

Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study. Cancer. 1987;60(S8):2035-41.

Akbayir O, Corbacioglu A, Goksedef BPC, Numanoglu C, Akca A, Guraslan H, et al. The novel criteria for predicting pelvic lymph node metastasis in endometrioid adenocarcinoma of endometrium. Gynecol Oncol. 2012;125(2):400-3.

Chi DS, Barakat RR, Palayekar MJ, Levine DA, Sonoda Y, Alektiar K, et al. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. Int J Gynecol Cancer. 2008;18(2):269-73.

Muallem MZ, Sehouli J, Almuheimid J, Richter R, Joukhadar R, Plett H. Risk factors of lymph nodes metastases by endometrial cancer: a retrospective one-center study. Anticancer Res. 2016;36(8):4219-25.

Chan JK, Cheung MK, Huh WK, Osann K, Husain A, Teng NN, et al. Therapeutic role of lymph node resection in endometrioid corpus cancer. Cancer. 2006;107(8):1823-30.

Lutman CV, Havrilesky LJ, Cragun JM, Secord AA, Calingaert B, Berchuck A, et al. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol. 2006;102(1):92-7.

Abu-Rustum NR, Iasonos A, Zhou Q, Oke E, Soslow RA, Alektiar KM, et al. Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma? Am J Obstet Gynecol. 2008;198(4):457-e1.

Polterauer S, Khalil S, Zivanovic O, Abu-Rustum NR, Hofstetter G, Concin N, et al. Prognostic value of lymph node ratio and clinicopathologic parameters in patients diagnosed with stage IIIC endometrial cancer. Obstet Gynecol. 2012;119(6):1210-8.

Wang X, Huang Z, Di W, Lin Q. Comparison of D&C and hysterectomy pathologic findings in endometrial cancer patients. Arch Gynecol Obstet. 2005;272(2):136-41.

Frumovitz M, Singh DK, Meyer L, Smith DH, Wertheim I, Resnik E, et al. Predictors of final histology in patients with endometrial cancer. Gynecol Oncol. 2004;95(3):463-8.

Mariani A, Dowdy SC, Cliby WA, Gostout BS, Jones MB, Wilson TO, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: A paradigm shift in surgical staging. Gynecol Oncol. 2008;109(1):11-8.

Toptaş T, Şimşek T, Karaveli Ş. Prognostic risk factors for lymph node involvement in patients with endometrial cancer. Turk J Obstet Gynecol. 2017;14(1):52.

Solmaz U, Mat E, Dereli M, Turan V, Gungorduk K, Hasdemir P, et al. Lymphovascular space invasion and cervical stromal invasion are independent risk factors for nodal metastasis in endometrioid endometrial cancer. Aust N Z J Obstet Gynaecol. 2015 Feb;55(1):81–6.

Widschwendter P, Bauer E, De NG, Bekes I, Janni W, Scholz C, et al. Influence of prognostic factors on lymph node involvement in endometrial cancer: a single-center experience. Int J Gynecol Cancer. 2018;28(6):1145-52.

Kang S, Kang WD, Chung HH, Jeong DH, Seo SS, Lee JM, et al. Preoperative identification of a low-risk group for lymph node metastasis in endometrial cancer: a Korean gynecologic oncology group study. J Clin Oncol. 2012;30(12):1329-34.

Lee JY, Jung DC, Park SH, Lim MC, Seo SS, Park SY, et al. Preoperative prediction model of lymph node metastasis in endometrial cancer. Int J Gynecol Cancer. 2010;20(8):1350-5.

Kamura T, Yahata H, Shigematsu T, Ogawa S, Amada S, Kaku T, et al. Predicting pelvic lymph node metastasis in endometrial carcinoma. Gynecol Oncol. 1999;72(3):387-91.

Todo Y, Sakuragi N, Nishida R, Yamada T, Ebina Y, Yamamoto R, et al. Combined use of magnetic resonance imaging, CA 125 assay, histologic type, and histologic grade in the prediction of lymph node metastasis in endometrial carcinoma. Am J Obstet Gynecol. 2003;188(5):1265-72.

Luomaranta A, Leminen A, Loukovaara M. Prediction of lymph node and distant metastasis in patients with endometrial carcinoma: a new model based on demographics, biochemical factors, and tumor histology. Gynecol Oncol. 2013;129(1):28-32.

Bendifallah S, Genin AS, Naoura I, Buffet NC, Chapelon FC, Haddad B, et al. A nomogram for predicting lymph node metastasis of presumed stage I and II endometrial cancer. Am J Obstet Gynecol. 2012;207(3):197-e1.

Kang S, Todo Y, Odagiri T, Mitamura T, Watari H, Kim JW, et al. A low-risk group for lymph node metastasis is accurately identified by Korean gynecologic oncology group criteria in two Japanese cohorts with endometrial cancer. Gynecol Oncol. 2013;129(1):33-7.

Todo Y, Okamoto K, Hayashi M, Minobe S, Nomura E, Hareyama H, et al. A validation study of a scoring system to estimate the risk of lymph node metastasis for patients with endometrial cancer for tailoring the indication of lymphadenectomy. Gynecol Oncol. 2007;104(3):623–628.

Koskas M, Genin AS, Graesslin O, Barranger E, Haddad B, Darai E, et al. Evaluation of a method of predicting lymph node metastasis in endometrial cancer based on five pre-operative characteristics. Eur J Obstet Gynecol Reprod Biol. 2014;172:115-9.

Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol. 2015;27(1):16-41.

Rossi EC, Kowalski LD, Scalici J, Cantrell L, Schuler K, Hanna RK, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol. 2017;18(3):384-92.

Touhami O, Trinh XB, Gregoire J, Sebastianelli A, Renaud MC, Grondin K, et al. Predictors of non-sentinel lymph node (non-SLN) metastasis in patients with sentinel lymph node (SLN) metastasis in endometrial cancer. Gynecol Oncol. 2015;138(1):41-5.

Raimond E, Ballester M, Hudry D, Bendifallah S, Daraï E, Graesslin O, et al. Impact of sentinel lymph node biopsy on the therapeutic management of early-stage endometrial cancer: results of a retrospective multicenter study. Gynecol Oncol. 2014;133(3):506-11.

Levine DA, Network CGAR. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67.